Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AIM · NYSE · Biological Products, (No Diagnostic Substances)
Aim Immunotech (AIM) · oqro.io/stocks/AIM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.1436−0.005 (−3.36%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Aim Immunotech (AIM) filed 11 open-market purchases in the last 90 days; the latest was filed on Nov 13, 2026.
Since 2005, Aim Immunotech insiders reported 161 open-market purchases and 11 sales on Forms 4 and 5, with purchases in 18 different years, most recently 2026.
No open-market sale by an insider of Aim Immunotech (AIM) was filed with the SEC in the last 90 days.
No trade in Aim Immunotech (AIM) was disclosed by a member of Congress in the last 12 months.
Aim Immunotech's next results are expected on Nov 16, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−90.2% (−$1.32) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $1.46 on Nov 13, 2025 to $0.1436 on Nov 13, 2026 (−90.2%). Disclosed in this range: 11 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Ocala, Fl.
Last 12 months
−90.2%
Market value
$4.37M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1M shares sold short (3.3% of shares outstanding), −7.2% vs the previous count, 2.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$26K
+4.0% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$6.28M
Debt $3.62M, cash $9.9M, at Jun 30, 2026
Net income, last 12 months
−$14.3M
Operating profit covers interest -9.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 10, 2026.
Revenue, fiscal 2025
$88K
−48.2% vs the year before
Net income, fiscal 2025
−$14M
A loss for the year
Shares outstanding
30.4M
As of Aug 7, 2026
Traded Nov 6 – Nov 11, 2026 · largest single transaction ~$5.4K
Nov 11, 2026~$5.2K · 35K sh @ $0.149
Nov 10, 2026~$5.4K · 39K sh @ $0.138
DetailsOfficial recordNov 9, 2026~$5.1K · 31K sh @ $0.162
DetailsOfficial recordNov 6, 2026~$2K · 13K sh @ $0.158
DetailsOfficial recordInsider buying
Traded Nov 6 · filed the same day
Since the trade −7.3% · S&P 500 +2.6% · to Nov 13
The CEO of Aim Immunotech paid $3.2K out of pocket for Aim Immunotech shares. Shares held went up 11% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
0 certified in FY2026 Q3, vs 0 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Aug 10, 2026
More than 30 days ago
Next results, expected
Nov 16, 2026
Purchases after results
8%
7 of 93 insider purchases since 2016 came within 30 days after a results announcement
From Aim Immunotech's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Aim Immunotech's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Said its annual or quarterly report would be late
NT 10-Q on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Aim Immunotech reported 161 open-market purchases and 11 sales since 2005; purchases in 18 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $44K11×11 trades | — |
| 2025 | $131K10×10 trades | — |
| 2024 | $183K15×15 trades | $8841×1 trade |
| 2023 | $150K8×8 trades | — |
| 2021 | $80K3×3 trades | — |
| 2020 | $75K3×3 trades | — |
| 2019 | $276K8×8 trades | — |
| 2018 | $176K18×18 trades | — |
| 2017 | $196K9×9 trades | — |
| 2016 | $129K12×12 trades | — |
| 2015 | $170K13×13 trades | — |
| 2012 | $13K2×2 trades | — |
| 2011 | $12K1×1 trade | — |
| 2010 | $1.09M11×11 trades | $315K9×9 trades |
| 2009 | $27K5×5 trades | — |
| 2008 | $10K1×1 trade | — |
| 2006 | $347K9×9 trades | $40K1×1 trade |
| 2005 | $239K22×22 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Nov 13, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up free